Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)

Phase 2 Terminated 6 enrolled M.D. Anderson Cancer Center

Non-randomizedSingle-groupOpen-labelTreatment

To find out if the combination of repotrectinib and fulvestrant can control the disease in participants with metastatic invasive lobular carcinoma.

Evaluation	Drug	Modality	Dose	Route
Subject	Fulvestrant	Small molecule	—	Oral
Subject	Repotrectinib	Small molecule	—	Intravenous